ArriVent BioPharma Stock Forecast - Simple Exponential Smoothing
| AVBP Stock | 23.22 1.98 7.86% |
The Simple Exponential Smoothing forecasted value of ArriVent BioPharma Common on the next trading day is expected to be 23.22 with a mean absolute deviation of 0.67 and the sum of the absolute errors of 40.10. ArriVent Stock Forecast is based on your current time horizon.
As of today the rsi of ArriVent BioPharma's share price is below 20 . This suggests that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Using ArriVent BioPharma hype-based prediction, you can estimate the value of ArriVent BioPharma Common from the perspective of ArriVent BioPharma response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Exponential Smoothing forecasted value of ArriVent BioPharma Common on the next trading day is expected to be 23.22 with a mean absolute deviation of 0.67 and the sum of the absolute errors of 40.10. ArriVent BioPharma after-hype prediction price | USD 23.37 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of ArriVent BioPharma to cross-verify your projections. ArriVent BioPharma Additional Predictive Modules
Most predictive techniques to examine ArriVent price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for ArriVent using various technical indicators. When you analyze ArriVent charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
ArriVent BioPharma Simple Exponential Smoothing Price Forecast For the 25th of January
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of ArriVent BioPharma Common on the next trading day is expected to be 23.22 with a mean absolute deviation of 0.67, mean absolute percentage error of 0.75, and the sum of the absolute errors of 40.10.Please note that although there have been many attempts to predict ArriVent Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that ArriVent BioPharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
ArriVent BioPharma Stock Forecast Pattern
| Backtest ArriVent BioPharma | ArriVent BioPharma Price Prediction | Buy or Sell Advice |
ArriVent BioPharma Forecasted Value
In the context of forecasting ArriVent BioPharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. ArriVent BioPharma's downside and upside margins for the forecasting period are 19.18 and 27.26, respectively. We have considered ArriVent BioPharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of ArriVent BioPharma stock data series using in forecasting. Note that when a statistical model is used to represent ArriVent BioPharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 115.9854 |
| Bias | Arithmetic mean of the errors | -0.0593 |
| MAD | Mean absolute deviation | 0.6683 |
| MAPE | Mean absolute percentage error | 0.0313 |
| SAE | Sum of the absolute errors | 40.1 |
Predictive Modules for ArriVent BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ArriVent BioPharma Common. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ArriVent BioPharma After-Hype Price Prediction Density Analysis
As far as predicting the price of ArriVent BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in ArriVent BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of ArriVent BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
ArriVent BioPharma Estimiated After-Hype Price Volatility
In the context of predicting ArriVent BioPharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on ArriVent BioPharma's historical news coverage. ArriVent BioPharma's after-hype downside and upside margins for the prediction period are 19.33 and 27.41, respectively. We have considered ArriVent BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
ArriVent BioPharma is not too volatile at this time. Analysis and calculation of next after-hype price of ArriVent BioPharma Common is based on 3 months time horizon.
ArriVent BioPharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as ArriVent BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ArriVent BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with ArriVent BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.37 | 4.04 | 0.00 | 0.01 | 0 Events / Month | 1 Events / Month | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
23.22 | 23.37 | 0.65 |
|
ArriVent BioPharma Hype Timeline
ArriVent BioPharma Common is presently traded for 23.22. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.01. ArriVent is forecasted to increase in value after the next headline, with the price projected to jump to 23.37 or above. The average volatility of media hype impact on the company the price is insignificant. The price gain on the next news is projected to be 0.65%, whereas the daily expected return is presently at 0.37%. The volatility of related hype on ArriVent BioPharma is about 18363.64%, with the expected price after the next announcement by competition of 23.21. Net Loss for the year was (80.49 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next forecasted press release will be in 5 to 10 days. Check out Historical Fundamental Analysis of ArriVent BioPharma to cross-verify your projections.ArriVent BioPharma Related Hype Analysis
Having access to credible news sources related to ArriVent BioPharma's direct competition is more important than ever and may enhance your ability to predict ArriVent BioPharma's future price movements. Getting to know how ArriVent BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how ArriVent BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MGTX | MeiraGTx Holdings PLC | 0.00 | 0 per month | 0.00 | (0.05) | 5.08 | (5.18) | 14.00 | |
| REPL | Replimune Group | (0.20) | 3 per month | 0.00 | (0.09) | 5.56 | (5.32) | 20.44 | |
| ATXS | Astria Therapeutics | 0.00 | 0 per month | 1.04 | (0.06) | 2.11 | (1.67) | 6.54 | |
| MBX | MBX Biosciences Common | 0.00 | 0 per month | 4.04 | 0.22 | 14.40 | (7.47) | 25.38 | |
| DNA | Ginkgo Bioworks Holdings | 0.00 | 0 per month | 0.00 | (0.09) | 8.16 | (6.79) | 28.96 | |
| IOVA | Iovance Biotherapeutics | 0.00 | 0 per month | 4.11 | 0.05 | 11.81 | (7.38) | 37.34 | |
| VALN | Valneva SE ADR | 0.00 | 0 per month | 2.21 | 0.02 | 4.83 | (3.36) | 14.16 | |
| ERAS | Erasca Inc | 0.00 | 0 per month | 2.55 | 0.33 | 15.04 | (4.76) | 50.26 | |
| ARVN | Arvinas | 0.00 | 0 per month | 3.16 | 0.11 | 5.91 | (4.42) | 28.90 | |
| DAWN | Day One Biopharmaceuticals | (0.02) | 19 per month | 3.62 | 0.13 | 13.81 | (6.53) | 39.62 |
Other Forecasting Options for ArriVent BioPharma
For every potential investor in ArriVent, whether a beginner or expert, ArriVent BioPharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. ArriVent Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in ArriVent. Basic forecasting techniques help filter out the noise by identifying ArriVent BioPharma's price trends.ArriVent BioPharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ArriVent BioPharma stock to make a market-neutral strategy. Peer analysis of ArriVent BioPharma could also be used in its relative valuation, which is a method of valuing ArriVent BioPharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
ArriVent BioPharma Market Strength Events
Market strength indicators help investors to evaluate how ArriVent BioPharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ArriVent BioPharma shares will generate the highest return on investment. By undertsting and applying ArriVent BioPharma stock market strength indicators, traders can identify ArriVent BioPharma Common entry and exit signals to maximize returns.
ArriVent BioPharma Risk Indicators
The analysis of ArriVent BioPharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in ArriVent BioPharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting arrivent stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.16 | |||
| Semi Deviation | 3.25 | |||
| Standard Deviation | 4.04 | |||
| Variance | 16.35 | |||
| Downside Variance | 12.41 | |||
| Semi Variance | 10.57 | |||
| Expected Short fall | (3.80) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for ArriVent BioPharma
The number of cover stories for ArriVent BioPharma depends on current market conditions and ArriVent BioPharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that ArriVent BioPharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about ArriVent BioPharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
ArriVent BioPharma Short Properties
ArriVent BioPharma's future price predictability will typically decrease when ArriVent BioPharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of ArriVent BioPharma Common often depends not only on the future outlook of the potential ArriVent BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ArriVent BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 31.5 M | |
| Cash And Short Term Investments | 218.9 M |
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma's price analysis, check to measure ArriVent BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma is operating at the current time. Most of ArriVent BioPharma's value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma's price. Additionally, you may evaluate how the addition of ArriVent BioPharma to your portfolios can decrease your overall portfolio volatility.